Dr. Greg Marchand is available to journalists, producers and editors for expert commentary across women’s health and surgery. Each topic below is backed by peer-reviewed work from the Marchand Institute, so you can cite published evidence alongside the quote.
To book an interview, contact Maria A. Sainz, Director of Communications and Media Relations, at maria@marchandobgyn.com or (480) 999-0905. Interviews are available in English and Spanish, and we aim to respond the same business day. Full contact details and boilerplate are in our Newsroom and Press Kit.
Surgical Technique and Minimally Invasive Surgery
Single-port and ultra-minimally invasive gynecologic surgery
Dr. Marchand holds the world record for performing a hysterectomy through the smallest incision ever recorded and has published a textbook on single-port advanced laparoscopic hysterectomy. He can explain what “single-port,” “mini-laparoscopy” and “LESS” actually mean for a patient, and where the real limits of these techniques lie.
Related published work: meta-analyses of miniature laparoscopy versus single-port laparoscopy in hysterectomy; laparoendoscopic single-site versus conventional laparoscopy in ovarian cystectomy, adnexectomy and ectopic pregnancy.
Hysterectomy: choosing a route and what outcomes actually differ
The Institute has published repeatedly on vaginal versus laparoscopic versus robotic hysterectomy, including a meta-analysis in Obstetrics & Gynecology. Dr. Marchand can speak to recovery time, pain, complication rates and how a patient should ask about surgical route.
Robotic surgery and vNOTES: where the evidence is and is not
Dr. Marchand has published meta-analyses of robotic versus non-robotic single-site hysterectomy, robotic versus laparoscopic radical hysterectomy for early stage cervical cancer, and vaginal natural orifice transluminal endoscopic surgery. He is a useful counterweight for stories about surgical technology marketing, because the data do not always favor the newer device.
Morcellation and contained tissue extraction
Dr. Marchand is the inventor of a patented non-morcellating surgical tissue removal system and has published a meta-analysis of contained versus uncontained morcellation. He has been outspoken that banning morcellation outright is the wrong response to a narrow-indication risk, and can explain the trade-off in plain terms.
Cancer Risk and Prevention
Ovarian cancer prevention and opportunistic salpingectomy
This is one of the Institute’s central research lines. Dr. Marchand patented the “Marchand Salpingectomy,” published a meta-analysis of salpingectomy versus tubal ligation for sterilization in the American Journal of Obstetrics and Gynecology, and most recently a meta-analysis of changes in epithelial ovarian cancer incidence associated with salpingectomy. He was quoted by STAT News on the rise of fallopian tube removal. In August 2026 he was quoted by MDLinx in two pieces on opportunistic salpingectomy: one on the access barriers patients still face after Dobbs, and one on the surgical trade-offs of adding the procedure to another operation.
Cervical cancer screening, HPV and self-collected sampling
The Institute published a 2025 systematic review and meta-analysis in AJOG Global Reports comparing patient-collected with clinician-collected cervical cytology. Dr. Marchand can explain what self-collection means for access, and what it does and does not change about accuracy.
Ovary removal, cancer risk and long-term health
Dr. Marchand has commented for The Epoch Times and others on the cardiovascular consequences of oophorectomy, and has published on risk-reducing salpingo-oophorectomy at the time of prolapse surgery.
Pregnancy, Obstetrics and Medication Safety
Cesarean technique, uterine closure and cesarean scar defects
The Institute has published two major analyses on single- versus double-layer uterine closure, most recently a time-stratified meta-analysis of randomized trials in the American Journal of Obstetrics & Gynecology MFM. Dr. Marchand can explain what a cesarean “niche” or isthmocele is and why it matters for future pregnancies.
Cannabis and substance exposure in pregnancy
The Institute’s meta-analysis of birth outcomes after in-utero marijuana exposure was published in JAMA Network Open and is its most-cited paper, with a further updated meta-analysis published in 2025. This has been covered by WebMD, U.S. News & World Report, Contemporary OB/GYN and MDLinx.
Medication and vaccine safety in pregnancy
Dr. Marchand has published meta-analyses on COVID-19 vaccination in pregnancy, RSVpreF vaccination in pregnancy, and maternal and neonatal outcomes of COVID-19 infection, and has commented widely on acetaminophen, hydralazine, sertraline, melatonin and antidepressant use in pregnancy. He is comfortable discussing where evidence is strong, where it is weak, and where it is genuinely contested.
Labour, delivery and operative vaginal birth
A 2026 systematic review in the American Journal of Perinatology compared neonatal ischemic encephalopathy risk in operative vaginal delivery versus cesarean at complete dilation. Dr. Marchand has also published on induction practice and misoprostol dosing, and speaks regularly on labour induction and pain management including nitrous oxide.
Cervical insufficiency and cerclage
Dr. Marchand’s laparoscopic and transabdominal cerclage work has been published in the European Journal of Obstetrics, Gynecology and Reproductive Biology and the Journal of Minimally Invasive Gynecology, and his technique was incorporated into the OB/GYN core competencies curriculum at Rutgers New Jersey Medical School.
Gynecologic Conditions
Endometriosis
Dr. Marchand has served as Principal Investigator on multiple endometriosis drug trials, including the SPIRIT and RAQUEL programs, and has published on gabapentin for chronic female pelvic pain. He can discuss diagnostic delay, medical versus surgical management, and how to read a new endometriosis drug headline.
Uterine fibroids and abnormal uterine bleeding
Published work includes a network meta-analysis of first- and second-generation endometrial ablation devices in BMJ Open, and a meta-analysis of supracervical hysterectomy versus endometrial ablation. Dr. Marchand has also been Principal Investigator on fibroid drug trials.
Pelvic organ prolapse and urogynecology
The Institute has published meta-analyses of laparoscopic versus vaginal uterosacral ligament suspension in the Journal of Minimally Invasive Gynecology, and of uterine-preserving versus uterus-removing prolapse repair. A systematic review of Bulkamid for female stress urinary incontinence will be presented at SLS MISWeek 2026.
Pediatric and adolescent gynecology
The Institute published a 2025 systematic review in the International Journal of Women’s Health showing outcome differences between gynecologic and pediatric surgeons operating on adnexal masses in children, along with a meta-analysis of conservative surgical treatment for acute ovarian torsion in young patients.
Contraception, sterilization and over-the-counter access
Dr. Marchand has published a narrative review of salpingectomy, tubal ligation and hysteroscopic occlusion for sterilization and has commented frequently on over-the-counter oral contraception, IUDs, and birth control for PCOS.
Menopause and hormone therapy
Dr. Marchand has authored expert reviews on menopausal hormone therapy for vasomotor symptoms and osteoporosis prevention and was quoted by Medscape Medical News on proactive menopause management.
Research Methodology and the Practice of Medicine
How to read a meta-analysis
Because the Institute produces systematic reviews at high volume, Dr. Marchand is a good source when a new meta-analysis makes headlines. He can explain heterogeneity, risk of bias, why two reviews of the same question can disagree, and what a confidence interval that crosses one actually means for readers.
Surgical education, simulation and the OB/GYN workforce
Dr. Marchand directs an SLS-accredited fellowship and an advanced laparoscopic and robotic simulation laboratory, and has published on residency application patterns and on assessing innate surgical ability. He has commented for Fox News and ABC15 on the OB/GYN shortage.
Choosing a surgeon and evaluating credentials
Dr. Marchand has spoken publicly on how patients can identify an unqualified or inappropriately credentialed surgeon, and on what accreditations such as Center of Excellence and Master Surgeon designations actually require.
Booking and Ground Rules
We are happy to speak on the record, on background, or to provide a written statement. We can turn around short written comment quickly and can usually accommodate same-day live hits. We will tell you when a question falls outside Dr. Marchand’s expertise rather than guessing, and we will tell you when the evidence is genuinely uncertain.
Dr. Marchand and the Institute have no financial relationships with pharmaceutical or medical device companies and accept no industry funding, which we are glad to state on the record in any story.
Contact: Maria A. Sainz, Director of Communications and Media Relations — maria@marchandobgyn.com — (480) 999-0905